Gentherm Incorporated — Q3 2023 Form 10-Q
Reporting period: Three and nine months ended September 30, 2023. Unless otherwise stated, amounts below are in U.S. dollars. Gentherm supplies automotive thermal-management and comfort products and medical patient-temperature-management products.
Financial performance
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $366.2 million | $333.0 million | $1,102.1 million | $861.3 million |
| Gross margin | $86.2 million; 23.5% | $80.4 million; 24.1% | $255.3 million; 23.2% | $203.8 million; 23.7% |
| Operating income | $23.7 million | $22.8 million | $45.7 million | $44.7 million |
| Net income | $15.8 million | $9.8 million | $22.3 million | $28.6 million |
| Diluted EPS | $0.48 | $0.29 | $0.67 | $0.86 |
- Revenue drivers: Q3 revenue increased 10.0%, led by automotive volume, favorable currency effects and acquired businesses, partly offset by pricing and other items. Nine-month revenue rose 28.0%; the increase included $152.8 million from acquisitions and $105.4 million from automotive volume, offset in part by currency and pricing/customer-recovery effects.
- Profitability: Q3 net income improved year over year, while gross margin narrowed by 0.6 percentage points. Nine-month net income fell despite higher revenue and operating income, principally reflecting higher interest expense, a $19.5 million medical goodwill impairment, and increased operating expenses.
- Cash flow: Nine-month operating cash flow was $80.0 million, versus $13.0 million in 2022. Investing used $16.9 million, including $26.5 million of capital expenditures; financing used $60.8 million, including $31.1 million of share repurchases and $27.2 million of debt repayments. Cash ended at $154.4 million, up slightly from $153.9 million at year-end 2022.
- Liquidity and debt: Current assets were $700.6 million and current liabilities $312.3 million at September 30. Total debt was $207.9 million, mostly revolving borrowings bearing a 6.79% rate; cash therefore exceeded debt by approximately $53.6 million. The $500 million revolving facility had $293.0 million of additional borrowing availability, subject to conditions. The company reported covenant compliance.
Material changes and unusual items
- Automotive revenue rose 10.0% in Q3 and 28.9% for the first nine months; medical revenue increased 9.7% and 4.3%, respectively. Acquired Alfmeier and Dacheng businesses contributed to year-over-year comparisons.
- Q3 cost of sales increased 10.8%, broadly in line with revenue growth; management cited higher volumes, wage inflation, acquired-business costs and a non-automotive electronics inventory charge, partly offset by lower freight, duties and material costs. Nine-month gross margin was also affected by inflation and $5.5 million of inventory write-downs associated with the planned exit of the non-automotive electronics business.
- A $19.5 million non-cash goodwill impairment was recorded in the Medical segment in Q2 after slower-than-expected revenue growth and lower projected cash flows. Further impairment could result if forecasts weaken or targets are missed.
- Q3 interest expense was $3.4 million, compared with $0.7 million of net interest income a year earlier; nine-month net interest expense increased to $9.4 million from $1.3 million, primarily reflecting higher rates and less benefit from the interest-rate swap.
- Foreign-currency translation reduced nine-month other comprehensive income by $11.8 million; Q3 translation loss was $16.5 million.
Outlook, management commentary and risks
- Fit-for-Growth 2.0 targets sales above $2 billion and a high-teens adjusted EBITDA margin by 2026. Planned levers include manufacturing productivity and footprint optimization, value engineering, sourcing and Alfmeier synergies; these are targets, not guarantees.
- A September 2023 plan will relocate certain Greenville, South Carolina manufacturing activities to Monterrey, Mexico. Expected costs are $14–$18 million, with annual benefits estimated at $5–$6 million; completion is expected by the end of 2025. Management cautions actual costs, timing and savings may differ.
- Management estimated that North American OEM strikes, if known strike-related idling continued through November, could reduce Q4 2023 revenue by approximately $15–$20 million. A tentative Ford agreement had been announced October 25; the filing warns prolonged or expanded strikes could cause further disruption.
- Third-party S&P Global Mobility forecasts cited in the filing projected 8.6% growth in 2023 light-vehicle production in Gentherm’s key markets. This is an industry forecast, not company revenue guidance.
- Automotive new-business awards were $520 million in Q3 and $1.7 billion year to date at September 30; the company reported $2.0 billion year to date through the filing date. Awards are projected lifetime revenue, not firm orders, and depend on customer forecasts and other assumptions.
- Key risks include automotive production and labor disruptions, inflation and incomplete cost recovery, supply-chain availability, foreign-exchange and floating-rate exposure, and medical-segment performance. Semiconductor purchase commitments totaled $25.6 million. The company reported no material pending litigation and no material change to previously disclosed risk factors.
Important facts for investors to verify
- Whether automotive strikes affected Q4 production and revenue, and whether any disruption persisted or expanded.
- Progress toward the Greenville-to-Monterrey transition, including actual restructuring costs, timing and realized annual savings.
- Medical-segment revenue and profitability against forecasts, including whether further goodwill impairment indicators emerge.
- Gross-margin recovery and the extent to which inflation, customer pricing and cost-recovery actions affect results.
- Available revolver capacity, covenant headroom, interest-rate exposure and cash-flow demands from debt, capital spending and repurchases.
- Conversion of automotive awards into firm programs and sales, and the assumptions supporting the 2026 targets.